City Therapeutics Inc. (NASDAQ: CTY) is a Healthcare company (Biotechnology) with a market capitalization of $170M. The Maz Rating grades it against the other companies in its sector.
City Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $17.50, City Therapeutics Inc. trades at 0.0x sales, with an EV/EBITDA of 1.6. Over the last twelve months it generated about $8.3B of revenue. It runs a gross margin of 70.1%, an operating margin of 35.4% and a net margin of 22.4%. It shows return on equity of 18.3%, return on invested capital of 11.4% and a free cash flow yield of 1331.5%. On the balance sheet: a debt-to-equity ratio of 0.59 and a current ratio of 0.73. Over the past 52 weeks the share price ranged from $15.81 to $23.88, with a beta of 0.00.
City Therapeutics Inc. does not currently pay a dividend.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.